Drug intelligence / Profile preview

MLL3 siRNA

Development stage
Preclinical
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral
01

Overview

MLL3 siRNA is a small interfering RNA designed to silence the expression of the MLL3 (Myeloid/Lymphoid or Mixed-Lineage Leukemia 3) gene, also known as KMT2C. MLL3 is a histone lysine methyltransferase that primarily catalyzes the monomethylation of histone H3 lysine 4 (H3K4me1) at enhancer regions, a key epigenetic modification for gene activation. In research contexts, particularly concerning rheumatoid arthritis (RA), MLL3 siRNA is used to investigate the role of MLL3 in the activation of synovial fibroblasts (RASFs). Studies have shown that siRNA-mediated depletion of MLL3 suppresses the expression of pro-inflammatory chemokines such as CCL5, CXCL10, and CXCL11, suggesting that MLL3 contributes to the inflammatory environment in RA joints through enhancer-mediated epigenetic regulation.

Other names
siRNA-mediated depletion of MLL3MLL3-targeting siRNAMLL-3-targeting siRNAMLL 3-targeting siRNA
02

Targets

KMT2C (KMT2C / MLL3)

Beyond the preview

Go deeper on MLL3 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MLL3 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call